Search

everythinglearnresearchcommunity

for

Search:↓

Both finasteride and drospirenone treatments improved symptoms and increased pregnancy rates in women with polycystic ovary syndrome.

A patient with Alopecia Areata had complete hair regrowth after using the drug baricitinib.

Steroid treatment improved both gut and nerve symptoms in a man with Cronkhite–Canada syndrome.

Upadacitinib helped regrow hair and maintain ulcerative colitis remission.

Baricitinib is effective and cost-efficient for treating severe alopecia areata in adults.

Biologic therapies can cause various adverse events, but allergy/immunology clinicians can manage them.

Adalimumab improved folliculitis decalvans in most patients.

GLP-1 receptor agonists can help skin conditions but may cause hair loss and other skin issues.

The drug Olumiant is now approved to treat severe hair loss from alopecia and can also be used for some hospitalized COVID-19 patients.

Ruxolitinib may effectively treat APS-1 by reducing harmful immune responses.

JAK inhibition may help manage autoimmune conditions in Down syndrome.

Abemaciclib can cause skin, hair, and nail problems, leading some patients to stop using it.

Baricitinib may effectively treat oral lichen planus.

New drugs targeting the JAK-STAT pathway show promise for treating inflammatory skin diseases.

Blocking certain immune signals can reduce skin damage from radiation therapy.

Baricitinib improved hair loss and arthritis in a lupus patient.

Type I interferons may help treat skin issues in lupus and dermatomyositis.

Intravenous cyclophosphamide effectively treated steroid-resistant lupus cystitis and peritonitis.

Baricitinib is effective as a treatment for severe hair loss.

Ruxolitinib reduced inflammation and improved symptoms in APECED patients but may cause anemia and weight gain.

Iressa often causes skin issues like acne and dryness in lung cancer patients.

Cyclosporin A significantly increases hair growth in certain areas of mice.

The combination therapy effectively treats infertility in PCOS without major side effects.

Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.

Mimosine dipeptides are promising for treating hyperpigmentation and inflammation.

Secukinumab reduces immune activity in hidradenitis suppurativa skin.

A woman developed hair loss after starting a treatment with adalimumab, suggesting this medication might cause hair loss.

Tofacitinib may be an effective and safe treatment for adolescent alopecia areata.